Recent Updates
Recently added Catalysts
VRDN Positive Sentiment

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

Tuesday, October 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Viridian Therapeutics will report its third quarter 2026 financial results on November 4, 2026. The company will hold a conference call at 8:00 a.m. ET to discuss these results and provide a business update. This event is an opportunity for stakeholders to gain insights into the company's performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Viridian Therapeutics is focused on best-in-class medicines.
  • The company is actively engaging with investors through a conference call.
  • Upcoming financial results may indicate positive business developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
VRDN-003
Phase 3 · Thyroid Eye Disease

Full Press Release Details

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A w

Frequently Asked Questions

When will Viridian report its Q3 2026 results?

Viridian will report its Q3 2026 results on November 4, 2026.

What time is the conference call on November 4?

The conference call will be held at 8:00 a.m. ET.

What is the focus of Viridian Therapeutics?

Viridian focuses on developing medicines for autoimmune and rare diseases.

How can stakeholders participate in the call?

Stakeholders can join the call to discuss financial results and business updates.

ShareAdd on Google
Tags: VRDN Viridian Therapeutics financial results biotechnology conference call
Last updated: Oct 20, 2026

Biotech snapshot

Cash runway
$982M liquidity · $35M/mo burn
~26 mo
Minimal dilution risk
Lead asset
VRDN-003Phase 3
Thyroid Eye Disease →

Catalyst track record

+77%
best trade around VRDN's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for VRDN.

See every catalyst's timing & PoA →